

Press Release

Klinge Pharma and Aristo Pharma to acquire Physiogel in Europe; Megalabs to acquire Physiogel, Sunmax and Clindo in South America

HOLZKIRCHEN (Feb. 27, 2020) – Klinge Pharma GmbH has acquired the brand Physiogel from GlaxoSmithKline (GSK) in Germany, Austria and France with the signing of the contract on Feb. 27, 2020. With the acquisition of Physiogel, Klinge Pharma is strengthening its OTC portfolio and entering a new therapeutic field, dermatology. In Poland, Spain, Portugal, Italy and the Ukraine, Physiogel has been acquired by Aristo Pharma GmbH; in Brazil, Mexico, Chile and Colombia, Physiogel, Sunmax and Clindo has been acquired by Megalabs. Klinge Pharma is responsible for coordination in Europe and South America. Dr. Ines Bohn, Managing Director of Klinge Pharma, is looking forward to the cooperation: "Aristo Pharma, Megalabs and Klinge Pharma are united by the pursuit of innovation and the strive for growth. The collaboration will be characterised by a high degree of constructiveness and professionalism in order to make the products Physiogel, Sunmax and Clindo available to even more patients as effective dermatological treatment options."

Companies on growth trajectory

With this acquisition, Klinge Pharma is strengthening its presence in pharmacies. The company also plans to expand its dermatological portfolio to include prescription products. Klinge Pharma, which already has a large portfolio in the gastrointestinal area, is thus setting up dermatology as a strategic growth area. Aristo Pharma, with the acquisition of the Polish dermatological company Axxon in 2018, is continuing its growth course with Physiogel in further European countries. For Megalabs, dermatology is also a key area in South America where it has a long successful track record driven by its line Medihealth including a wide portfolio of products present in most of the Latin American markets. Physiogel, Sunmax and Clindo will be relevant brands for the Brazilian operation, strengthen Megalab's position in the market and complementing several launches currently in the pipeline.

The planned acquisition is subject to the standard conditions and is expected to be completed in the second quarter. Financial details of the purchase will not be disclosed.



About Klinge Pharma

A medium-sized and innovative company – Klinge Pharma has been offering over-the-counter and prescription-only drugs and medical devices of the highest quality for more than 80 years. The well-proven Venostasin® was discovered in 1933. The main focuses are gastrointestinal medications with classics such as Vomex A® for nausea and vomiting and new products such as Gelsectan® for treating irritable bowel symptoms, Carvomin® digestive medicine for gastrointestinal disorders and DiaVerde® for acute diarrhea. As partners of doctors and pharmacists, the employees of Klinge Pharma are committed to the health of people.

Together for health. This is what Klinge Pharma stands for with its current headquarters in Holzkirchen at Tegernsee.

About Aristo Pharma

Aristo Pharma was founded in 2008 and established itself as one of the most important pharmaceutical companies within a very short time. The Aristo Pharma Group has followed a growth-oriented path, which more than 1,500 employees enthusiastically help to shape. The headquarters are based in the federal capital of Berlin which offers an attractive environment, whilst also being a strategically important location for the nationally active sales network and the German and Spanish production sites.

The product range is focused on a wide selection of the most important substances in the generics market alongside well-known original products. In addition, Aristo Pharma offers a comprehensive range of herbal medicines, some of which have been used for decades, as well as modern medical devices.

About Megalabs

Megalabs is a leading branded specialty Latin American pharmaceutical company, committed to healthcare, strategically oriented towards innovation, and dedicated to affordable therapeutic solutions.

Currently present in 18 countries with more than 7,700 employees including a highly professional sales force of more than 3,000 FTEs, it holds an excellent reputation within the medical communities of the continent. 24% of doctors in Latin America prescribe its products and 42,000 Megalabs products are prescribed every day by health professionals. Its continuous growth is supported by 17 owned production sites, a highly diversified portfolio with more than 1,800 products and 6 R&D centres where more than 80 projects are carried out per year. Megalabs is a future-oriented company holding a consolidated reputation as one of the key Pharma players in Latin America.



Contact:

MW Office PR

Silvia Schmidt
Leopoldstr. 150
80804 Munich
Germany

Tel.: +49 (0) 89-96086-372

Fax: +49 (0) 89-96086-50

E-Mail: silvia.schmidt@mwoffice.de

www.mwoffice.de

Please send us a specimen copy in case of reprinting/publication.